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Background/aim: Narrowband UVB (Nb UVB) treatment is commonly used for the management of psoriasis and atopic dermatitis,
and is less often used for vitiligo in children. The aim of this study was to evaluate the efficacy and short-term safety of Nb UVB
phototherapy in children diagnosed with vitiligo retrospectively
Materials and methods: A total of 26 patients younger than 18 years with the diagnosis of vitiligo and managed with Nb UVB
phototherapy as documented in archive records were evaluated. Clinical response was assessed according to repigmentation of the
lesions: good response when there was more than 75% repigmentation, moderate response when there was 25%–74% repigmentation,
poor response when repigmentation was less than 24%, and unresponsive when there was no pigmentation and new lesions occurred.
Results: A total of 26 patients received Nb UVB treatment; 14 were girls and 12 were boys. The age at onset of the disease varied between
2 and 18 years, with a mean age of onset of 10.07 ± 4.53 years. Repigmentation rate of >75% was detected in 45.4% of cases.
Conclusion: Nb UVB phototherapy seems to be a well-tolerated effective and safe treatment option in children, especially those
unresponsive to topical treatment and those with widespread lesions. However, long-term risks such as photocarcinogenesis and
photoaging should kept in mind.
Key words: Pediatric, narrowband UVB, phototherapy, vitiligo

1. Introduction
Vitiligo is an idiopathic and autoinflammatory disease
of the skin affecting 1% of the population, characterized
by depigmented macules and patches. The disorder
generally manifests in childhood and young adulthood
with almost half of the patients reported to be less than
20 years of age (1). Although various topical and systemic
agents have been used in the treatment of the disease,
no consensus has been reached and as of yet there is no
curative type of treatment. Phototherapy has been used
in many diffuse dermatological diseases unresponsive
to topical treatment agents as an alternative to systemic
treatment methods, while its use is limited specifically
in children due to early skin aging and potential skin
cancer risks. Narrowband UVB (Nb UVB) treatment is
commonly and successfully used in childhood for the
treatment of psoriasis and atopic dermatitis and less
frequently in the treatment of vitiligo (2–4). The purpose
of this study was to retrospectively evaluate the efficacy
and short-term safety of Nb UVB in children diagnosed
with vitiligo.
* Correspondence: serkanyazici@uludag.edu.tr

2. Materials and methods
2.1. Patients
Medical records of a total of 26 patients with an age of
<18 years who were treated with Nb UVB phototherapy
for vitiligo between January 2009 and January 2014 at our
clinic were evaluated retrospectively. Age, sex, duration
of the disease, presence of family history, comorbidities,
skin type, vitiligo subtype, topical treatment the patient
had used, duration of Nb UVB treatment, total number of
sessions, total cumulative dose, response to treatment, and
adverse effects secondary to the treatment were recorded.
Lesions were grouped as generalized, focal, and acrofacial
according to the Fitzpatrick classification (5).
2.2. Phototherapy protocol
Written informed consent was obtained from all parents
and standard phototherapy precautions were taken in all
cases; eyes were covered and the genitals were protected.
A Daavlin cabin (Daavlin, Bryan, OH, USA) with a
Philips TL-01/100W fluorescent light (Philips Company,
Eindhoven, the Netherlands) was used as the phototherapy
source. The Nb UVB treatment was administered twice
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weekly. The initial irradiation dose was defined according
to skin type (1: 75 mJ/cm2; 2: 100 mJ/cm2; 3: 150 mJ/cm2)
and was increased by 10% in each session according to
the erythema response; the total number of sessions was
determined according to the clinical response.
2.3. Treatment response
Clinical response was evaluated according to the
repigmentation in the lesions. The response was accepted
to be good, intermediate, and weak when the percentage
of repigmentation was ≥75%, 25%–74%, and <24%,
respectively. Patients with no pigmentation despite
treatment and those with newly arising lesions were
accepted as unresponsive (6).
2.4. Statistical analysis
SPSS 20.0 for Windows was used for statistical analysis.
Data were summarized and organized into tables and
analyzed using descriptive statistics, given as mean ±
standard deviation, median, minimum, maximum, and
percentages.
3. Results
Clinical demographic properties of the patients and
parameters of the treatment are summarized in Table 1. The
26 children included 14 females and 12 males who received
Nb UVB treatment. The age when the disorder started
varied between 2 and 18 years with a mean age at onset of
10.07 ± 4.53 years. The duration of the disease prior to Nb
UVB varied between 6 months and 10 years with a mean
length of 3.15 ± 2.86 years. According to the Fitzpatrick
classification, 20 patients had skin type 2 (76.9%), four had
skin type 1, and three had skin type 3. The most commonly
seen subtype of vitiligo was generalized vitiligo in 16
(61.5%) of the cases, and the remaining subtypes were focal
vitiligo in four and acrofacial vitiligo in six cases. There was
no patient with segmental vitiligo. Three of the 26 patients
had presence of the thyroid antibody alone, and three had
thyroid hormone disorder. Twenty patients had no thyroid
disease. Folic acid deficiency, vitamin B12 deficiency, low
hemoglobin, and ferritin deficiency accompanied the
diagnoses in two, one, three, and two cases, respectively.
All patients had used topical treatment agents prior to Nb
UVB phototherapy. Topical steroids alone; topical steroids
and topical calcipotriol; topical steroids and topical
immunomodulator treatment; topical steroids, topical
calcipotriol, and topical immunomodulator treatment;
and cosmetic creams were used in six, three, six, four, and
seven cases, respectively. Five of 26 patients dropped out
of the treatment of their own will, while 19 completed
the treatment according to the response and two patients
are still continuing the treatment course. The number of
sessions of the 19 patients who completed the treatment
course varied between 13 and 163 with a mean number
of sessions of 83.36 ± 47.6. The lowest, greatest, and mean
cumulative dose was 5.21 J/cm2, 100.52 J/cm2, and 34.66 ±
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28.13 J/cm2. Nine of the patients responded well (47.36%),
while four responded intermediately and four weakly.
Two patients were accepted as unresponsive. No serious
adverse effects were detected in all but one patient, who
had mild erythema.
4. Discussion
Many types of noncurative treatment have been used
in the management of vitiligo. Topical steroids are
inexpensive, easy to apply, and may be effective in cases
of limited involvement; however long-term use of steroids
is not recommended due to the risk of skin atrophy (7,8).
Topical calcipotriol, on the other hand, has been suggested
as an alternative to potent steroids, rather than its solo use
(8). Oral psoralen plus ultraviolet A (PUVA) treatment is
not recommended in children under 12 years of age due
to its phototoxicity risk (9). Topical PUVA may be used in
children with an involvement of less than 20% of the body
surface and is a safe method of treatment (10).
Use of Nb UVB phototherapy was first reported in
the management of vitiligo in 1997 and it was found to
be superior to topical PUVA treatment (11). Njoo et al.
reported Nb UVB use in children to be an efficient and
safe method (12). Later on, in 2005, Kanwar et al. (13) and
Brazzelli et al. (6) reported their experiences with Nb UVB
use in pediatric patients with vitiligo, and Ersoy-Evans
et al. (2) and Sen et al. (3) from Turkey reported their
own experiences with the use of Nb UVB phototherapy
in pediatric patients. A comparison of our results with
the results of other studies is given in Table 2. The rate of
repigmentation of 75% (47.36%) was compatible with the
rates of repigmentation reported in the studies of Njoo et
al. (12) and Brazzelli et al. (6). The repigmentation rate was
found to be higher in the present study in spite of the lower
cumulative dose, different from the results in the study by
Percivalle et al., who found a repigmentation rate of 14.3%
in spite of a higher cumulative dose (14). Although the
duration of treatment was long, the reason for the lower
cumulative dose may be due to continuous dose reduction
and thus inadequate dose increases were secondary to
the incompatibility of the patients to treatment. In the
literature, complete and good response rates (>75%
repigmentation) in pediatric cases with vitiligo have been
reported to vary between 14.3% and 75%. This rate was
found to be 47.36% in the present case series. No side
effects were observed, except in one patient who had
reversible erythema of the chin.
In conclusion, our study suggests that Nb UVB
phototherapy seems to be a well-tolerated, effective, and
safe method of treatment in the short term for pediatric
patients, especially patients unresponsive to topical agents
or with diffuse lesions. However, its long-term potential
risks, such as photocarcinogenesis and photoaging, should
be kept in mind while planning treatment.
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Table 1. Clinical demographics of the patients and parameters of treatment.

Parameter

n, %

n, total
♀/♂
Age at onset of disease (years)
Mean ± SD
Duration of disease prior to Nb UVB (years)
Mean ± SD
Skin type
1
2
3
Vitiligo type
Generalized
Focal
Segmental
Acrofacial
Thyroid function disorder
Hashimoto thyroiditis
Hyperthyroidism
Hematological disorder
None

26
14/12

Folate deficiency
Low hemoglobin
Vitamin B12 deficiency
Low ferritin
Prior treatment
TS + calcipotriol
TS
TS + TI + calcipotriol
TS + TI
Cream with vitamin content
Nb UVB treatment
Completed treatment
Receiving treatment
Dropped out
Number of Nb UVB sessions (patients completing the treatment = 19)
Mean ± SD
Median; min, max
Cumulative dose (J/cm2)
Mean ± SD
Median; min, max
Clinical response (n = 11)
Good response (≥75)
Intermediate response
No response
Poor response

2
3
1
2

10.07 ± 4.53
3.15 ± 2.86
4
20, 76.9
3
16, 61.5
4
6
3
3
20

3
6
4
6
7
19
2
5
83.36 ± 47.6
87.0; 13, 163
34.66 ± 28.13
30.90 ± 5.2, 100
9, 47.36
4
2
4

TS, Topical steroids; TI, topical immunomodulator; SD, standard deviation.
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Table 2. Literature search of Nb UVB treatments in pediatric cases of vitiligo.
Characteristics

Njoo et al.
(12)

Kanwar and
Dogra (13)

Brazzelli
et al. (6)

Ersoy-Evans
et al. (2)

Percivalle
et al. (14)

Sen et al. (3)

This study

Year

2000

2005

2005

2008

2008

2015

2016

n

51

20

10

9

28

36

26

Sex, F/M

31/20

13/7

4/6

?

20/8

20/16

14/12

Mean age (min to max)

9.9 (4 to 16)

(5 to 14)

9.7 (6 to 14) 10.6 ± 3.3

10.1 (3 to 15)

12.5 ± 3.5

10.07 ± 4.53

Duration of disease

4

1.63

3.15

-

2.96

-

3.15

Sessions/week

2

3

2

3

2

3

2

Duration of treatment

11.1 ± 2.0

12

5.6

8.5 ± 5.8

10 ± 3.4

Number of sessions

78.3 ± 19.9

-

49.33

14 (9 to 107) 62.5 ± 20

-

14.26 ± 8.78

125.4 ± 59.5

83.36 ± 47.6

Cumulative dose (J/cm2)

91.3 ± 46.6

39.7 ± 12.3

51.6

70 (9–301)

156.1 ± 79.4

231.9 ± 140.1

34.66 ± 28.13

Repigmentation (>75%)

27 (53%)

15 (75%)

5 (50%)

4 (50%)*

4 (14.3%)

16 (44.5%)

9 (47.36%)

*Repigmentation of >50%.
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